The second-generation ALK-TKIs, Alectinib, has been shown a good therapeutic effect on intracranial lesions because of its advantage of penetrating the blood-brain barrier.[7] While NSCLC is characterized as high heterogeneity and the sensitivity of ALK-TKIs in patients with different types of ALK-fusion variant subtypes leading to significant differences in clinical efficacy.[3] Therefore, it is necessary to guide clinical treatment effectively by gene detection. This evidence concerns the gene ALK and non-small cell lung carcinoma.